We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Next-Generation Benchtop Diagnostic Platform Delivers Rapid Multi-Gene Test Results

By LabMedica International staff writers
Posted on 27 Nov 2023

In today’s rapidly advancing healthcare sector, the implementation of multi-gene testing is increasingly crucial. More...

This method efficiently uses limited tissue samples and significantly speeds up the time to get critical results. Now, a benchtop diagnostic platform for fully integrated analysis of molecular biomarker signatures with a 4-hour automated workflow allows hospitals and pathology labs to bring this advanced technology in-house, leading to quicker results and enhanced coordination in patient care.

BIOTYPE GmbH (Dresden, Germany) has significantly upgraded its MODAPLEX platform, making it easier for research and clinical labs to conduct sophisticated molecular analyses swiftly and automatically. The MODAPLEX system stands out for its ability to simultaneously detect and assess crucial biomarkers using a simple process. With an efficient workflow that takes less than four hours, the platform provides pathologists and clinicians with rapid and precise results. It enables the simultaneous measurement of key RNA and DNA biomarkers from a single sample, facilitating prompt initiation of optimal therapy and contributing to healthcare system efficiency.

BIOTYPE is now introducing an enhanced version of its hardware platform, featuring simplified software for automated analysis of cancer-related RNA and DNA biomarkers. The open-system nature of the MODAPLEX platform allows third parties, including molecular testing system developers and pharmaceutical companies, to create and distribute their own assays. This strategy broadens the range of available tests and makes the MODAPLEX platform more appealing to users who prefer sourcing test kits from various providers.

"The launch of the next-generation MODAPLEX system also marks our entry into the international business for molecular testing platforms," said Dr Norman Gerstner, CEO of BIOTYPE GmbH. "Last year, we repositioned the company in the rapidly growing precision medicine market. In addition to molecular tests for highly specialized diagnostics of complex diseases, we are now expanding our portfolio to include software and instruments. In addition, MODAPLEX is making an important contribution to meeting the growing demand for sophisticated technologies for multi-gene testing. MODAPLEX maximizes the use of existing tissue samples and reduces critical turnaround times."

Related Links:
BIOTYPE GmbH


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Urine Analyzer
respons® UDS100
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.